Systemic lupus erythematosus: new diagnostic and therapeutic approaches
S Lazar, JM Kahlenberg - Annual review of medicine, 2023 - annualreviews.org
Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …
Interferon target-gene expression and epigenomic signatures in health and disease
Multiple type I interferons and interferon-γ (IFN-γ) are expressed under physiological
conditions and are increased by stress and infections, and in autoinflammatory and …
conditions and are increased by stress and infections, and in autoinflammatory and …
[HTML][HTML] Trial of anifrolumab in active systemic lupus erythematosus
Background Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
1 investigated for the treatment of systemic lupus erythematosus (SLE), did not have a …
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
Background Type I interferons are involved in systemic lupus erythematosus (SLE)
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
pathogenesis. In a phase 2 trial, anifrolumab, a human monoclonal antibody to type I …
A randomized, placebo‐controlled phase III extension trial of the long‐term safety and tolerability of anifrolumab in active systemic lupus erythematosus
Objective To explore long‐term safety and tolerability of anifrolumab 300 mg compared with
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …
Antibodies to watch in 2021
H Kaplon, JM Reichert - MAbs, 2021 - Taylor & Francis
In this 12th annual installment of the Antibodies to Watch article series, we discuss key
events in antibody therapeutics development that occurred in 2020 and forecast events that …
events in antibody therapeutics development that occurred in 2020 and forecast events that …
The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps
F Apel, L Andreeva, LS Knackstedt, R Streeck… - Science …, 2021 - science.org
Neutrophil extracellular traps (NETs) are structures consisting of chromatin and antimicrobial
molecules that are released by neutrophils during a form of regulated cell death called …
molecules that are released by neutrophils during a form of regulated cell death called …
Selective JAKinibs: prospects in inflammatory and autoimmune diseases
AT Virtanen, T Haikarainen, J Raivola, O Silvennoinen - BioDrugs, 2019 - Springer
Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers
and Activators of Transcription) pathway, play a central role in the pathogenesis of …
and Activators of Transcription) pathway, play a central role in the pathogenesis of …
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III …
Objectives To characterise the efficacy and safety of anifrolumab in patients with systemic
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic …
Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes
S Bannister, B Kim, J Domínguez-Andrés, G Kilic… - Science …, 2022 - science.org
Trained immunity describes the capacity of innate immune cells to develop heterologous
memory in response to certain exogenous exposures. This phenomenon mediates, at least …
memory in response to certain exogenous exposures. This phenomenon mediates, at least …